Compass Therapeutics (CMPX) Total Debt (2018 - 2021)

Compass Therapeutics has reported Total Debt for 3 years, with the latest figure at $3.7 million in Q3 2021.

• Quarterly Total Debt fell 66.54% year-over-year to $3.7 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $3.7 million (down 66.54% YoY) and the FY2020 annual result came in at $9.3 million, down 37.23% from the prior year.
• Total Debt eased to $3.7 million in Q3 2021 per CMPX's latest filing, from $7.5 million in the prior quarter.
• Over five years, Total Debt peaked at $14.9 million in Q4 2019 and troughed at $3.7 million in Q3 2021.
• A 3-year average of $9.9 million and a median of $10.3 million in 2020 frame the typical range for Total Debt.
• The sharpest annual moves came in 2020 and 2021: Total Debt slumped 37.23% in 2020, then plunged 66.54% in 2021.
• Over 3 years, Total Debt stood at $14.9 million in 2019, then plunged by 37.23% to $9.3 million in 2020, then plunged by 59.89% to $3.7 million in 2021.
• According to Business Quant data, Total Debt over the past three periods registered $3.7 million, $7.5 million, and $9.3 million for Q3 2021, Q1 2021, and Q4 2020 respectively.